- Home
- KPRX
as 07-05-2024 4:00pm EST
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | ENCINITAS |
| Market Cap: | 14.3M | IPO Year: | N/A |
| Target Price: | $18.00 | AVG Volume (30 days): | 61.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -11.34 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.60 - $8.98 | Next Earning Date: | 08-06-2024 |
| Revenue: | $16,000,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | -81.82% |
Latest Kiora Pharmaceuticals Inc. News
KPRX Breaking Stock News: Dive into KPRX Ticker-Specific Updates for Smart Investing
Newsfile
6 days ago
Biotech Executive Lisa Walters-Hoffert Joins Kiora Pharmaceuticals' Board of Directors
Newsfile
12 days ago
Vitreoretinal Surgeon and Key Thought Leader Roger Goldberg, M.D., Joins Kiora Pharmaceuticals' Scientific Advisory Board
Zacks
19 days ago
Is Kiora Pharmaceuticals (KPRX) Stock Undervalued Right Now?
Simply Wall St.
a month ago
Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) stock most popular amongst retail investors who own 39%, while hedge funds hold 31%
The Telegraph
a month ago
Italian energy company targets Britain for fleet of 20 mini-nukes
Simply Wall St.
a month ago
It Might Not Be A Great Idea To Buy StepStone Group LP (NASDAQ:STEP) For Its Next Dividend
Simply Wall St.
a month ago
Is Now The Time To Put Planet Fitness (NYSE:PLNT) On Your Watchlist?
Simply Wall St.
a month ago
Don't Buy Banc of California, Inc. (NYSE:BANC) For Its Next Dividend Without Doing These Checks
Share on Social Networks:
Disclaimer
The information presented on this page, "KPRX Kiora Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.